Pyrimidine Crystal Forms for Stable Brain-Penetrant HER2 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HER2 inhibitors face challenges with limited brain penetration and stability, particularly in treating brain metastasis, and require improved chemical and physical stability for effective therapeutic use.
Innovation Solution
Development of specific crystal forms of 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N—((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, including free-form and acid-bound crystals, which exhibit enhanced stability, oral absorbability, and brain penetration properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HER2 inhibitors (Lapatinib, Neratinib) are used as substrates of p-gp or Bcrp, then HER2 inhibitory activity is achieved, but brain penetration properties are limited
Solution Approach 1:
The patent modifies the chemical structure of HER2 inhibitors by introducing specific substituents (e.g., cyclopropylethynyl group at position 6, acryloyl group at position 1) to change the molecular parameters. These structural modifications alter the compound's interaction with transporters like P-gp and Bcrp, thereby improving brain penetration while maintaining HER2 inhibitory activity.
2Stability of the object's composition
If multiple crystal forms are developed for compound (I), then stability and oral absorbability are improved, but crystal identification and manufacturing complexity increase
Solution Approach 1:
The patent segments the crystal forms into distinct types (Type I, Type II, Type III) with well-defined and differentiated characteristics. Each crystal type has unique X-ray diffraction patterns, melting points, and stability profiles, allowing for easy identification and selection. This segmentation simplifies manufacturing by providing clear criteria for quality control and batch consistency.
Solution Approach 2:
The patent uses X-ray diffraction patterns as a form of 'fingerprint' identification for different crystal types. Each crystal form produces a distinctive diffraction pattern that serves as a reliable identifier, enabling quick and accurate crystal form determination during manufacturing and quality control processes.
3Reliability
If HER2 inhibitors are developed for brain metastasis treatment, then antitumor effects on primary tumors are achieved, but sufficient effects against brain metastatic cancer cannot be obtained
Solution Approach 1:
The patent introduces specific structural modifications to HER2 inhibitors, including the cyclopropylethynyl group at position 6 and acryloyl group at position 1, which change the molecular parameters to improve brain penetration. These parameter changes enable the compound to overcome the blood-brain barrier while maintaining its antitumor activity against both primary tumors and brain metastases.
Data Source
AI summary
A crystal of 7-((3R,5S)-1-acryloyl-5-methylpyrrolidin-3-yl)-4-amino-6-(cyclopropylethynyl)-N—((R)-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (compound (I)), and a crystal thereof with an acid (salt crystal or co-crystal) are provided.There are provided: a type II crystal of compound (I) with fumaric acid, having characteristic peaks at three or more diffraction angles (2θ±0.2°) selected from 5.5°, 6.8°, 9.3°, 13.4°, 15.3°, 16.3°, 18.5°, 19.8°, 22.0°, and 24.5° in a powder X-ray diffraction spectrum;a (free-form) type II crystal of compound (I) having characteristic peaks at three or more diffraction angles selected from 8.3°, 14.8°, 17.3°, 18.0°, 19.1°, 20.3°, 21.0°, 22.5°, 23.0°, and 26.2° in a powder X-ray diffraction spectrum;a (free-form) type I crystal of compound (I) having characteristic peaks at three or more diffraction angles selected from 9.9°, 11.7°, 13.2°, 17.7°, 18.1°, 18.8°, and 20.8° in a powder X-ray diffraction spectrum;a type V crystal of compound (I) with fumaric acid, having characteristic peaks at four or more diffraction angles selected from 6.9°, 9.4°, 10.2°, 13.7°, 21.1°, 23.6°, and 26.5° in a powder X-ray diffraction spectrum; anda type I crystal of compound (I) with fumaric acid, having characteristic peaks at four or more diffraction angles selected from 6.4°, 10.3°, 12.8°, 15.0°, 20.7°, 23.4°, and 26.6° in a powder X-ray diffraction spectrum.